Increased Prevalence of Carotid Artery Atherosclerosis in Rheumatoid Arthritis Is Artery-specific

HITOMI KOBAYASHI, JON T. GILES, JOSEPH F. POLAK, ROGER S. BLUMENTHAL, MARY S. LEFFELL, MOYSES SZKLO, MICHELLE PETRI, ALLAN C. GELBER, WENDY POST, and JOAN M. BATHON

ABSTRACT

Objective. Cardiovascular (CV) morbidity and mortality are increased in rheumatoid arthritis (RA). Prior investigations of the association of RA with measures of carotid atherosclerosis have yielded conflicting results. We compared carotid intima-media thickness (IMT) of both the common carotid (CCA) and proximal internal carotid (bulb-ICA) arteries, and plaque prevalence, between RA and non-RA participants.

Methods. Subjects with RA were participants in a cohort study of subclinical CV disease in RA. Non-RA controls were selected from the Multi-Ethnic Study of Atherosclerosis. Both groups underwent B-mode ultrasonography of the right and left CCA and bulb-ICA. Linear regression was used to model the association of RA status with CCA and bulb-ICA-IMT, and logistic regression for the association of RA status with plaque.

Results. We compared 195 RA patients to 198 non-RA controls. CV risk factors were similarly distributed, except for a higher prevalence of hypertension in the RA group. Mean adjusted bulb-ICA-IMT was higher in RA patients than controls (1.16 vs 1.02 mm, respectively; p < 0.001), while mean adjusted CCA-IMT did not differ significantly. After adjusting for CV risk factors, the odds of plaque were significantly increased in RA participants compared to controls (OR 2.41, 95% CI 1.26–4.61). The association of gender, age, smoking, and hypertension with bulb-ICA-IMT and plaque did not significantly differ by RA status. Interleukin 6 was strongly associated with bulb-ICA-IMT and plaque in controls but not in RA patients. In the RA group, shared epitope was associated with an increased prevalence of plaque.

Conclusion. Compared to controls, RA was associated with a higher prevalence and higher severity of atherosclerosis in the bulb-ICA but not the CCA. Our data suggest that future studies in RA that utilize carotid artery measurements should include assessment of the bulb-ICA. (First Release Feb 1 2010; J Rheumatol 2010;37:730–9; doi:10.3899/jrheum.090670)

Key Indexing Terms:
RHEUMATOID ARTHRITIS
CAROTID DISEASE
INFLAMMATION
ATHEROSCLEROSIS
EPIDEMIOLOGY

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects 1%–2% of adult populations. RA is associated with a reduced life expectancy compared to the general population, primarily due to increased cardiovascular (CV) morbidity and mortality. Rates of myocardial infarction are 2–3 times higher in RA patients than non-RA controls, and RA patients are more likely to experience silent ischemia. Adjustment for conventional CV risk factors does not account for the higher rates of CV events in RA populations, suggesting that rheumatoid inflammation is an independent risk factor for CV disease.

The detection of asymptomatic atherosclerosis in RA may enable identification of individuals at high risk for acute CV events who constitute optimal targets for early intervention. Carotid B-mode ultrasonography is a convenient noninvasive method for detecting subclinical atherosclerosis. Increased intima-media thickness (IMT) and the presence of plaque in the carotid arteries are strongly correlated with CV risk factors and generalized atherosclerosis, and are also strong predictors of future stroke and myocardial infarction in the general population.

A number of investigations of subclinical carotid artery disease using carotid ultrasonography have been reported in RA, but with conflicting results. Most of the non-US
studies have reported significantly higher mean IMT values in RA subjects compared to controls; however, many of these studies were small and thus were unable to adjust adequately for conventional CV risk factors\(^\text{12-19}\). In contrast, 2 large US studies found no difference in mean IMT level between RA and non-RA subjects\(^\text{20,21}\). Similarly, 6 of 8 non-US studies\(^\text{15,19}\), and one of the 2 US studies\(^\text{20}\), found no difference in plaque prevalence between the RA versus non-RA groups. Thus, an unambiguous association of RA with more severe subclinical carotid atherosclerosis has not been clearly demonstrated.

The inconsistency in these study results likely derives from methodological rather than biological differences, the most important of which may be differences in the definitions of plaque and IMT and different locations imaged in the carotid arteries. The internal carotid artery (ICA) and carotid bifurcation are anatomic sites with a predilection for development of atherosclerotic plaque, and some have argued that IMT measures from these sites may be a better estimate of true atherosclerosis than measures obtained from the common carotid artery (CCA)\(^\text{23}\). Despite this, very little is known in RA populations about artery-specific differences in IMT and their relationships to CV risk factors.

The primary aim of our study was to evaluate IMT in different carotid arteries, as well as overall prevalence of carotid plaque, in a large RA cohort and to compare these measures to a contemporaneous non-RA control group using identical protocols. Our secondary aims were: (1) to determine and compare the relationship of these carotid ultrasound variables to traditional and inflammatory CV risk factors in the 2 groups; and (2) to identify disease characteristics associated with higher IMT and greater plaque prevalence within the RA cohort.

**MATERIALS AND METHODS**

**Participants and enrollment.** RA subjects. ESCAPE RA (Evaluation of Subclinical Cardiovascular disease And Predictors of Events in Rheumatoid Arthritis) is a cohort study of the prevalence, progression, and risk factors for subclinical CV disease in men and women with RA\(^\text{24}\). It was designed with identical inclusion and exclusion criteria (except for the diagnosis of RA) to those of the Multi-Ethnic Study of Atherosclerosis (MESA), a population-based cohort study of subclinical CV disease with similar objectives. ESCAPE RA inclusion criteria were: (1) fulfillment of American College of Rheumatology criteria for the classification of RA\(^\text{25}\) of > 6 months; and (2) age 45–84 years. Exclusion criteria were: (1) prior self-reported physician-diagnosed myocardial infarction, heart failure, coronary artery revascularization, peripheral vascular (arterial) disease or procedures, implanted pacemaker or defibrillator devices, and current atrial fibrillation; (2) weight exceeding 300 pounds (due to imaging equipment limitations); and (3) computerized tomographic scan of the chest within 6 months prior to enrollment (to limit radiation exposure). One hundred ninety-five RA participants were recruited from the Johns Hopkins Arthritis Clinic and by referral from local rheumatologists from October 2004 through May 2006. Informed consent was obtained from all participants, and the study was approved by the Institutional Review Board of the Johns Hopkins Hospital.

Control subjects. The controls without RA were selected from MESA participants enrolled in the Baltimore Field Center. Frequency matching was used to select a control group with similar demographic characteristics as the RA group, using 16 substrata defined by gender (male/female), age (9-year increments), and race (Black/White). A description of MESA design and methods has been published\(^\text{26}\). In brief, MESA enrolled a multi-ethnic cohort of 6814 participants aged 45–84 years without clinically apparent CV disease from 6 US communities between 2000 and 2002, among whom 1086 were enrolled by the Johns Hopkins (Baltimore) Field Center. MESA participants who reported use of disease-modifying antirheumatic drugs (DMARD) that are typically used for the treatment of RA were excluded as potential controls. A total of one hundred ninety-eight MESA controls were available for the analyses.

**Assessments.** **Carotid imaging.** Ultrasound imaging of the carotid arteries was performed in ESCAPE-RA participants using MESA ultrasound procedures, technicians, and equipment (Logiq 700, General Electric Medical Systems). The probe frequency utilized for the ICA/bulb was 9 MHz, for the CCA 13 MHz, and for the pulsed Doppler studies 4.0 MHz. The imaging protocol involved obtaining a single longitudinal lateral view of the distal 10 mm of the right and left CCA and 3 longitudinal views in different imaging planes of each bulb-ICA. The bulb-ICA was defined as including both the carotid bulb, identified by the loss of parallel wall present in the CCA, and the 10-mm segment of the ICA distal to the tip of the flow divider that separates the external and internal carotid arteries.

Videotaped scans were analyzed at the MESA Ultrasound Reading Center. The baseline carotid scans of the MESA controls served as the comparator scans, and these were reanalyzed at the same time as the ESCAPE-RA scans by a single MESA reader blinded to RA status. Maximal IMT was measured in end-diastole at each of the near and far walls of the right and left CCA, and the anterior oblique, lateral, and posterior oblique views of the bulb-ICA, for a total of 16 IMT measurements per person. The mean maximal IMT of the CCA and bulb-ICA were obtained by averaging the maximal measurements from the near and far walls at each projection, from the right and left sides. When an atherosclerotic plaque was present at the measurement site, it was included in the IMT measurement. The presence of plaque was investigated in the ICA and carotid bulb. Plaque was defined per the Framingham study\(^\text{27}\) as focal protrusion into the lumen of the ICA/bulb with reduction in the lumen diameter of more than 25%. For internal carotid IMT measurements, intraobserver coefficient of variation was 6.93%, and interobserver coefficient of variation was 18.8%. For common carotid IMT measurements, intraobserver and interobserver coefficients of variation were 3.48% and 10.7%, respectively\(^\text{28}\).

**Covariate assessment.** ESCAPE RA used the same questionnaires, equipment, methods, and quality control procedures as MESA. Study coordinators were trained and certified by MESA trainers.

**Shared covariates.** Questionnaires were used to collect information on demographics, smoking, and family history. Resting blood pressure (BP) was measured 3 times in the seated position, and the average of the last 2 measurements was used in the analysis. Hypertension was defined by systolic BP > 140 mm Hg, diastolic BP > 90 mm Hg, or antihypertensive medication use. Diabetes was defined as a fasting serum glucose > 126 mg/dl or use of antidiabetic medications. Physical activity was assessed using the MESA activity recall questionnaire. Body mass index (BMI) was calculated as weight (kg) divided by height\(^2\) (m\(^2\)). Prescription and over-the-counter medications used in the preceding 2 weeks were documented from containers supplied by the participant.

**RA-specific covariates.** Forty-four joints in the RA participants were examined by a single trained assessor for swelling, tenderness, deformity, and surgical replacement or fusion. RA disease duration was calculated based on self-report from time of physician diagnosis. RA activity was calculated using the Disease Activity Score for 28 joints (DAS28) with CRP\(^\text{29}\). Functional limitation was assessed with the Stanford Health Assessment Questionnaire (HAQ)\(^\text{30}\). Current and past use of glucocorticoids, biologic and nonbiologic disease modifying agents (DMARD), and nonsteroidal antiinflammatory drugs (NSAID) were ascertained by interviews. Single-view, anterior-posterior radiographs of the hands and feet were obtained.
and scored using the Sharp-van der Heijde method31 by a single, trained radiologist blinded to patient characteristics. For 5 subjects with incomplete radiographic assessments, the missing score (hand or foot) was imputed from available data, based on a regression equation using data from the remaining subjects in the cohort.

Laboratory covariates. Fasting sera and plasma were separated by centrifugation and stored at ~70°C. All assays (except RA autoantibodies) were performed at MESA-designated laboratories using MESA quality control procedures. C-reactive protein (CRP), interleukin 6 (IL-6), fibrinogen, homocysteine, soluble intercellular adhesion molecule-1 (sICAM-1), and sE-selectin were measured as described32. Low density lipoprotein (LDL) cholesterol was estimated in plasma specimens having a triglyceride value < 400 mg/dl using the Friedewald equation. Positive rheumatoid factor (RF) was defined by a concentration > 40 units, and anticyclic citrullinated peptide (anti-CCP) antibodies by a concentration > 60 units.

HLA alleles bearing the “shared epitope” (SE) were investigated in the RA participants by direct sequencing of a polymerase chain reaction amplicon of exon 2 of the DRB1 gene using Allele SEQR HLA-DRB1 SBT kits (Abbott Molecular, Inc., Des Plaines, IL, USA). Ambiguous typing combinations, e.g., DRB1*0401/*0434, were further resolved using intron-ic reagents flanking exon 233. Capillary sequencing was performed on a 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) and sequencing data were analyzed withAssign software (Conexio Genomics, Applecross, W. Australia).

Statistical analysis. Means and standard deviations for normally distributed and medians and interquartile ranges for non-normally distributed variables were calculated. For categorical variables, counts and percentages were calculated. Differences in continuous variables between RA and control groups were compared using t-tests (for normally distributed variables) or the Kruskal-Wallis test (for non-normally distributed variables). Categorical variables were compared using the chi-square goodness of fit test or Fisher’s exact test.

Multivariate analyses were conducted in participants with complete clinical data (n = 393). We included covariates in the multivariate analyses that were unbalanced by exposure status (at the p < 0.20 level) or with strong association with the outcome, in order to account for the potential for residual confounding. Multivariable linear regression models adjusting for age, gender, and race/ethnicity were constructed to estimate adjusted means, 95% confidence intervals, and p values for CV risk factors. Linear regression was used to model the association of RA status with CCA- and bulb-ICA-IMT (as continuous variables). Logistic regression was used to model the association of RA status with plaque. Regression models included adjustments for pertinent demographic and CV risk factors including age, gender, race/ethnic background, highest education level, systolic and diastolic blood pressure (or presence of hypertension), diabetes, ever smoking, high density and LDL cholesterol, triglycerides, use of antihypertensive and lipid-lowering medications, IL-6, CRP, fibrinogen, glucose, amount of weekly intentional exercise, and BMI or waist circumference. Highly skewed variables (e.g., IMT, triglycerides, fibrinogen) were logarithmically transformed. Differences in the associations of CV risk factors with IMT and plaque by RA status were explored using ANCOVA.

Statistical calculations were performed using Intercooled Stata 9 (StataCorp, College Station, TX, USA). In all tests, a 2-tailed α of 0.05 was defined as the level of statistical significance.

RESULTS

Characteristics of RA subjects and MESA controls. One hundred ninety-six RA patients were recruited to the ESCAPE study and underwent carotid ultrasonography. Of these, 195 had CCA and bulb-ICA images that were suitable for analysis and thus constituted the study population. One hundred ninety-eight MESA controls who had carotid ultrasonography at the baseline visit served as controls; all CCA and bulb-ICA images were suitable for analysis. The baseline characteristics of the RA and MESA control subjects are presented in Table 1. As expected, due to frequency matching, there were no significant differences in age in the RA versus control group (mean ages 59.4 and 59.8 yrs, respectively), gender (60.2% vs 64.1% female), or proportion of Caucasians (86.2% vs 89.4%). CV risk factors were also balanced, except for modestly higher mean systolic and diastolic blood pressures in the RA participants. As expected, given their underlying inflammatory disorder, RA subjects had significantly higher median CRP, IL-6, fibrinogen, and s-ICAM levels than MESA controls.

Disease-related characteristics of the RA participants have been summarized24. Median disease duration was 9 years, and most subjects (78%) were seropositive for either RF or anti-CCP antibodies. About 70% of RA subjects had one or more HLA-DRB1 alleles bearing the SE. The median van der Heijde modified total Sharp score was 44. RA disease activity was low to moderate in most patients, as evidenced by a median DAS28 of 3.57. The majority (93%) of RA subjects were treated with DMARD, including 46% who were receiving biologics either as monotherapy or in combination with a nonbiologic DMARD. About 40% of RA patients were currently treated with glucocorticoids and nearly two-thirds with NSAID.

Carotid ultrasonographic measures of RA subjects and MESA controls. The unadjusted mean maximal bulb-ICA-IMT (hereafter referred to as “mean bulb-ICA-IMT”) was significantly higher in the RA group compared to the MESA control group (1.15 vs 1.04 mm, respectively; p = 0.002). Adjusted odds for conventional CV risk factors, the difference in mean bulb-ICA-IMT between the RA and MESA control groups remained significant (1.16 vs 1.02 mm; p = 0.001), and was more pronounced for men than women (Figure 1A; p for heterogeneity = 0.032), and for younger compared to older subjects (Figure 1B; p for heterogeneity = 0.016). When patients with plaque were excluded from the analysis, the difference in adjusted bulb-ICA-IMT between the RA and control participants remained statistically significant (1.01 vs 0.93 cm; p = 0.004). In contrast, neither the unadjusted (0.82 vs 0.84 mm; p = 0.25) nor the adjusted (0.83 vs 0.82 mm; p = 0.23) CCA-IMT were significantly different between the RA and control groups (data not shown).

The unadjusted prevalence of any plaque was higher in the RA subjects than in controls (21.5% vs 12.1%, respectively; p = 0.012; Figure 2). The prevalence odds ratios for carotid plaque for RA versus control subjects according to age group, with adjustment for other demographic and CV risk factors, are summarized in Figure 2. The adjusted odds of plaque was more than doubled in the RA group compared to controls (adjusted OR 2.20, 95% CI 1.21–4.32). The odds ratio was highest in the youngest category (45–54 yrs) and decreased with advancing age (p for heterogeneity = 0.042).
Inclusion of IL-6 or CRP in the above models comparing IMT and plaque in the RA and control groups did not statistically significantly change the magnitude of any of the differences between the RA and control groups (data not shown).

Association of selected risk factors with carotid outcomes according to RA status. Association of risk factors with carotid outcomes was compared between RA and MESA control participants (Table 2). Those risk factors with the strongest univariate associations with the outcomes, when the RA and non-RA groups were pooled (data not shown), were selected for analysis and included gender, age, hypertension, current smoking, and IL-6. Of note, other inflammation and vascular biomarkers (CRP, fibrinogen, E-selectin, and s-ICAM-1) were not significantly associated with the outcomes in the univariate analyses and therefore were not included in the statistical models. As shown in Table 2, most of the conventional CV risk factors exhibited similar associations with plaque, bulb-ICA-IMT, and CCA-IMT in the 2 groups, except the association of age with log CCA-IMT, which was modestly stronger in the MESA control group compared to the RA group (p for heterogeneity = 0.034). Interestingly, log IL-6 was strongly associated with plaque and log bulb-ICA-IMT in the MESA control group (β = 3.77 and 0.11, respectively), but was not associated with these outcomes in the RA group (β = 0.75 and –0.032, respectively; p for heterogeneity = 0.002 for both CCA-IMT and plaque). Figure 3 illustrates the unadjusted relationship of IL-6 values with bulb-ICA-IMT in the RA versus MESA control groups.

Association of RA characteristics with carotid plaque and IMT. The associations of RA characteristics and treatments with carotid plaque and with bulb-ICA-IMT in the RA group are summarized in Tables 3 and 4, respectively. Only HLA-DRB1 SE status was significantly associated with carotid plaque (Table 3). The presence of one or more SE alleles was associated with a near tripling of the adjusted prevalence odds ratio of plaque (OR 2.80, 95% CI 1.07–7.33). No RA characteristics were associated with bulb-ICA-IMT (Table 4).

### Table 1. Participant characteristics according to RA status.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>RA, n = 195</th>
<th>Controls, n = 198</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, yrs</td>
<td>59.4 ± 8.7</td>
<td>59.8 ± 8.7</td>
<td>0.61</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>118 (60.2)</td>
<td>127 (64.1)</td>
<td>0.42</td>
</tr>
<tr>
<td>Caucasian race, n (%)</td>
<td>169 (86.2)</td>
<td>177 (89.4)</td>
<td>0.34</td>
</tr>
<tr>
<td>Education, some college or higher, n (%)</td>
<td>147 (75.4)</td>
<td>153 (77.7)</td>
<td>0.59</td>
</tr>
<tr>
<td>Cardiovascular risk factors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes, n (%)</td>
<td>12 (6.1)</td>
<td>17 (8.6)</td>
<td>0.35</td>
</tr>
<tr>
<td>Weight, lbs</td>
<td>176 ± 39</td>
<td>177 ± 38</td>
<td>0.82</td>
</tr>
<tr>
<td>BMI</td>
<td>28.4 ± 5.3</td>
<td>28.8 ± 5.7</td>
<td>0.48</td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Present, &gt; 140/90, n (%)</td>
<td>54 (27.7)</td>
<td>35 (17.7)</td>
<td>0.018</td>
</tr>
<tr>
<td>Systolic BP, mm Hg</td>
<td>128 ± 19</td>
<td>122 ± 19</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Diastolic BP, mm Hg</td>
<td>76 ± 9</td>
<td>70 ± 9</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Use of antihypertensive medications, n (%)</td>
<td>79 (40.3)</td>
<td>56 (28.3)</td>
<td>0.012</td>
</tr>
<tr>
<td>Lipids</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol, mg/dl</td>
<td>195 ± 38</td>
<td>197 ± 36</td>
<td>0.69</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dl</td>
<td>116 ± 31</td>
<td>118 ± 30</td>
<td>0.45</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dl</td>
<td>55 ± 19</td>
<td>52 ± 14</td>
<td>0.11</td>
</tr>
<tr>
<td>Triglycerides, mg/dl</td>
<td>126 ± 92</td>
<td>128 ± 75</td>
<td>0.73</td>
</tr>
<tr>
<td>Use of lipid-lowering medications, n (%)</td>
<td>35 (17.9)</td>
<td>46 (23.2)</td>
<td>0.19</td>
</tr>
<tr>
<td>Cigarette smoking, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>23 (11.8)</td>
<td>19 (9.6)</td>
<td>0.49</td>
</tr>
<tr>
<td>Ever</td>
<td>115 (59.0)</td>
<td>107 (54.3)</td>
<td>0.35</td>
</tr>
<tr>
<td>Serum inflammatory markers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP, mg/l, median (IQR)</td>
<td>2.70 (1.18–7.57)</td>
<td>2.27 (0.92–4.73)</td>
<td>0.011</td>
</tr>
<tr>
<td>IL-6, pg/ml, median (IQR)</td>
<td>3.87 (1.77–7.92)</td>
<td>1.12 (0.73–1.89)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Fibrinogen, mg/dl, median (IQR)</td>
<td>335 (279–416)</td>
<td>327 (286–368)</td>
<td>0.039</td>
</tr>
<tr>
<td>E-selectin, ng/ml, median (IQR)*</td>
<td>48.6 (29.9–73.2)</td>
<td>47.7 (33.4–56.3)</td>
<td>0.56</td>
</tr>
<tr>
<td>s-ICAM-1, ng/ml, median (IQR)*</td>
<td>300 (229–371)</td>
<td>272 (233–307)</td>
<td>0.009</td>
</tr>
</tbody>
</table>

* E-selectin levels were available in only 24 and s-ICAM levels in only 73 of the controls. BMI: body mass index; BP: blood pressure; LDL/HDL: low/high density lipoprotein; CRP: C-reactive protein; IL-6: interleukin 6; s-ICAM: soluble intercellular adhesion molecule.
DISCUSSION

Our study demonstrates 3 novel findings: First, mean maximal IMT was higher in the bulb-ICA, but not the CCA, of RA patients compared to non-RA controls. Second, IL-6 (but not other risk factors) was more strongly associated with plaque and bulb-ICA-IMT in the non-RA group than the RA group. Third, in RA patients, the HLA-DRB1 SE was positively correlated with carotid plaque.

A number of previous investigations have reported on IMT and/or plaque prevalence in RA compared to non-RA populations, but with conflicting results. The discrepancies in results across these reports may be a result of significant methodological differences, including: (1) variability in excluding prior CV events; (2) inadequate power and/or failure to adjust for multiple conventional CV risk factors; (3) variability in exclusion of plaque from IMT measure-
ments; (4) variable definitions of plaque; (5) failure to blind the carotid scan readers; (6) comparison of RA patients to a noncontemporaneous control group; and (7) examination of the CCA only.

The design of our current study provides some advantages over previous reports. The ESCAPE-RA study was modeled closely after MESA, a contemporaneous cohort study of subclinical CV disease in the general population. We utilized MESA ultrasound procedures and risk factor definitions, MESA trained personnel, MESA-designated laboratories, and MESA participants as controls, in order to minimize error in the comparisons of RA to non-RA subjects. In addition, rather than relying on the preexisting analysis of the baseline MESA carotid scans, the MESA scans were reanalyzed alongside the ESCAPE-RA scans, and in a masked fashion by the same reader. Finally, we performed a systematic evaluation of IMT in both the CCA and ICA.

Our results demonstrate a higher mean maximal bulb-ICA-IMT in the RA subjects compared to MESA controls, even after adjusting for CV risk factors. In contrast, mean maximal CCA-IMT was not significantly different between groups. This may have important clinical implications in RA for future studies. Most carotid ultrasound studies in RA and in the general population have focused on measurement of the CCA. Indeed, increased baseline and increased progression of CCA-IMT in the general population are predictive of myocardial infarction.34-36 However,
in several37-39, but not all40, large population cohort studies in which both the bulb-ICA-IMT and CCA-IMT were evaluated, increased baseline and/or change per year in bulb-ICA-IMT conveyed a higher risk than CCA-IMT for incident myocardial infarction. Indeed, the mean change per year in IMT in the Carotid Atherosclerosis Progression Study23 was more than 30 times greater at the bulb-ICA than the CCA (0.032 vs 0.001 mm, respectively; p < 0.001), and only bulb-ICA-IMT progression correlated strongly with baseline CV risk factors. The higher values and greater variability in measurement of the bulb-ICA compared to the CCA largely reflect greater disease burden in the bulb-ICA; however, because the bulb-ICA is deeper than the CCA, technical challenges may also contribute to greater measurement variability in the bulb-ICA. In addition, the asymmetric nature of atherosclerotic plaque deposition requires sampling in multiple projections in order to decrease measurement variability.

Only 2 other RA studies measured IMT in both the ICA and CCA, but del Rincon, et al21 reported the average of the 2 arteries, rather than individual measurements. Gerli, et al41 measured IMT in 101 RA patients at multiple sites and found higher IMT in the RA patients compared to controls at the carotid bifurcation but not the ICA proper or the CCA, in agreement with our findings since the bifurcation area was included in our bulb-ICA measurement. However, Gerli, et al41 did not statistically adjust for conventional CV risk factors, many of which were present in substantially different frequencies or levels between the groups. Our study indicates a statistically significant increase in bulb-ICA-IMT in the RA compared to the control group, even after adjustment for these risk factors. Whether our finding of a site-specific difference in baseline IMT in RA versus non-RA subjects will translate into different risks of future CV events awaits longterm followup and verification in other RA cohorts. Nonetheless, our data suggest that future studies in RA that utilize carotid artery measurements should include assessment of the bulb-ICA.

### Table 3. Association of RA characteristics with carotid plaque (maximum carotid stenosis > 25%), n = 195.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Model 1, OR (95% CI)</th>
<th>Model 2, OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA duration, per year</td>
<td>1.01 (0.98, 1.04)</td>
<td>0.98 (0.94, 1.02)</td>
</tr>
<tr>
<td>Age at RA diagnosis, per year</td>
<td>1.03 (1.00, 1.06)</td>
<td>1.02 (0.98, 1.07)</td>
</tr>
<tr>
<td>DAS28-CRP, per unit</td>
<td>1.04 (0.76, 1.43)</td>
<td>1.13 (0.76, 1.67)</td>
</tr>
<tr>
<td>Any SE alleles</td>
<td>2.08 (0.90, 4.84)</td>
<td>2.80 (1.07, 7.33)*</td>
</tr>
<tr>
<td>Total Sharp score, per unit</td>
<td>1.00 (1.00, 1.01)</td>
<td>1.00 (0.99, 1.00)</td>
</tr>
<tr>
<td>HAQ, per unit</td>
<td>1.53 (0.98, 2.39)</td>
<td>1.33 (0.77, 2.31)</td>
</tr>
<tr>
<td>Log CRP, per unit</td>
<td>1.00 (0.78, 1.29)</td>
<td>0.82 (0.59, 1.13)</td>
</tr>
<tr>
<td>Log IL-6, per unit</td>
<td>0.92 (0.65, 1.32)</td>
<td>0.77 (0.50, 1.19)</td>
</tr>
<tr>
<td>Current prednisone use</td>
<td>0.86 (0.42, 1.75)</td>
<td>1.21 (0.51, 2.86)</td>
</tr>
<tr>
<td>Cumulative prednisone, per gram</td>
<td>0.99 (0.95, 1.03)</td>
<td>1.00 (0.95, 1.04)</td>
</tr>
<tr>
<td>Current nonbiologic DMARD</td>
<td>0.89 (0.35, 2.25)</td>
<td>1.00 (0.34, 2.92)</td>
</tr>
<tr>
<td>Current biologic DMARD</td>
<td>0.76 (0.38, 1.51)</td>
<td>0.93 (0.41, 2.10)</td>
</tr>
</tbody>
</table>

* p < 0.05. Model 1: crude model, no adjustment. Model 2: adjusted for systolic and diastolic blood pressure, antihypertensive use, HDL-C, LDL-C, use of lipid-lowering medications, diabetes, and ever smoking. DAS28: Disease Activity Score 28; SE: shared epitope; CRP: C-reactive protein; HAQ: Health Assessment Questionnaire; IL-6: interleukin 6; DMARD: disease modifying antirheumatic drug; HDL-C/LDL-C: high/low density lipoprotein cholesterol.
In addition to higher bulb-ICA-IMT, we also found a higher prevalence of plaque in the carotid arteries of RA patients compared to non-RA controls. This concordance is not surprising, since most plaque occurs in the ICA and bulb, and we included plaque in our IMT measurements. Our observation of increased prevalence of plaque in RA is in agreement with the study by Roman, et al. The higher prevalence odds ratio for plaque in our study in the youngest age stratum (45–54 yrs) of the RA versus non-RA groups suggests that RA plays a more significant role, relative to conventional risk factors, in promoting atherosclerosis in younger individuals, while conventional risk factors predominate in older ages, a hypothesis that is also supported by the studies of del Rincon, et al. and Roman, et al.

We compared the association of CV risk factors with carotid artery outcomes in RA versus non-RA participants. The associations of most of the conventional CV risk factors with plaque, CCA-IMT, and bulb-ICA-IMT were of similar strength between the 2 groups. With regard to inflammatory risk factors, only IL-6 levels were associated with plaque and bulb-ICA-IMT, but this relationship was observed only in the control group, an observation that is consistent with a study by Thakore, et al. in the general population. In individuals without chronic inflammatory diseases, IL-6 levels might be expected to be relatively constant over time, while IL-6 levels in RA are likely to vary widely with changing levels of disease activity and treatments. Although our data are cross-sectional, the associations depicted in Figure 3 indirectly support this notion and may explain the lack of relationship of IL-6 with carotid outcomes in the RA group. In other cross-sectional studies of RA populations, Roman, et al. also failed to find a relationship of inflammatory or vascular biomarkers (CRP, IL-6, vascular cell adhesion molecule, ICAM-1) with carotid plaque, while del Rincon, et al. saw a significant correlation of CRP and ESR with both carotid plaque and IMT.

Within the RA group, we also failed to observe a correlation of disease activity with carotid plaque or IMT. Other studies that looked at these variables have reported conflicting results. This may be because the risk for accelerated CV disease in RA is established in the preclinical phase, as suggested by Maradit-Kremers, et al., who reported a higher rate of myocardial infarction in patients with RA compared to controls prior to the RA diagnosis. The observation by us and others that the greatest difference in bulb-ICA-IMT and plaque between RA and controls was in the youngest category of patients further supports this concept.

The HLA-DRB1 SE alleles are highly correlated with the development and severity of RA, as well as with antibodies to citrullinated peptides. We observed a strong positive correlation of the presence of one or more copies of the SE with the presence of plaque but not with bulb-ICA-IMT. In other investigations in RA, an association of SE with impaired endothelium-dependent vasodilation and with CV-associated death were reported. Two recent genome-wide analyses of atherosclerosis in the general population did not reveal a signal in the MHC region. Thus, this genetic predisposition to accelerated atherosclerosis may be unique to RA.

The association of HLA-DRB1 with RA disease susceptibility appears to be explained in large part by its association with anti-CCP antibodies and, to a lesser extent, with RF. Surprisingly, however, RF and anti-CCP antibodies were not correlated in our study with plaque or bulb-ICA-IMT. These results differ from those of Gerli, et al., who reported an association between anti-CCP antibody and ICA-IMT. Studies in larger patient populations will be needed to elucidate the potential independent contributions of RA-specific autoantibodies and RA susceptibility genes in promoting or inhibiting atherosclerosis.

Some limitations of our study merit mention. First, we...
applied DMARD use as a means of excluding MESA control participants with RA. This method is more reliable than patient self-report of diagnosis of RA and is commonly used in epidemiological studies\textsuperscript{55}, however, we cannot exclude the possibility that we included some RA patients not currently taking DMARD. A second potential limitation relates to differences in referral patterns into the study (clinic-based for ESCAPE-RA vs community-based for MESA), which may have introduced selection bias. However, as the 2 cohorts were geographically compatible, it is likely that any bias related to selection would be limited in extent. Third, our analyses were cross-sectional and thus temporality cannot be determined. Finally, we measured a surrogate of CV disease rather than clinical CV events; nonetheless, both carotid plaque and IMT are well validated independent predictors of future stroke and myocardial infarction in the general population.

We observed a greater prevalence of plaque and greater IMT in the bulb-ICA but not the CCA of RA patients compared to non-RA controls, even after adjusting for conventional CV risk factors and other potential confounders. SE alleles appeared to convey risk for more severe atherosclerosis within the RA group. The role for vascular imaging in risk prediction for future CV events in RA is not yet clear. For now, aggressive management of both RA and conventional CV risk factors — in an attempt to limit future CV events — is prudent.

ACKNOWLEDGMENT

We are indebted to the ESCAPE RA Staff, Marilyn Towns, Michelle Jones, Patricia Jones, Marissa Hildebrandt, and Shawn Franckowiak, and to the staffs of the Johns Hopkins Bayview Medical Center General Clinical Research Center and the field center of the Baltimore MESA cohort and the MESA Coordinating Center at the University of Washington, Seattle. We are also indebted to the ESCAPE and MESA participants for the generous donation of their time and interest. Drs. Uzma Haque, Clifton Bingham III, Carol Ziminski, Jill Ratain, Ira Fine, Joyce Kopicky-Burd, David McGinnis, Andrea Marx, Howard Hauptman, Achini Perera, Peter Holt, Alan Matsumoto, Megan Clowse, Gordon Lam and others generously recommended their patients for this study.

REFERENCES


54. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-78.